Swiss National Bank Fulcrum Therapeutics, Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$2.83 - $13.99 $8,773 - $43,369	-3,100 Reduced 3.46%	86,500 $246,000
Q3 2022 Nov 09, 2022	BUY	$4.92 - $9.1 $133,824 - $247,520	27,200 Added 43.59%	89,600 $725,000
Q1 2022 May 09, 2022	BUY	$9.96 - $23.65 $61,752 - $146,630	6,200 Added 11.03%	62,400 $1.48 Million
Q4 2021 Feb 08, 2022	BUY	$14.0 - $28.44 $786,800 - $1.6 Million	56,200 New	56,200 $994,000

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $237M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.